Vaccine News and Research

Latest Vaccine News and Research

EMS Solutions provides free resources to help companies tackle this year's H1N1 flu pandemic

Emergency Management & Safety Solutions (EMS Solutions), the crisis planner for many Fortune 100 companies, international government agencies and large non-profit organizations, is providing free resources to help companies better prepare for and prevent transmission of this year's H1N1 flu pandemic. Today, over 180 countries have experienced the H1N1 virus outbreak and approximately 6,500 people have died -- including over 1,500 in North America, according to the European Center for Disease Prevention and Control.

12 Nov 2009

Drug companies collaborate with nonprofit organizations to fight "neglected" diseases in the developing world

Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. Those hard-to-treat diseases include malaria, tuberculosis, dengue fever, and other conditions. That's the topic of the cover story scheduled for the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

12 Nov 2009

Adamis Labs secures orders from three major wholesale distributers in U.S.

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that its wholly owned subsidiary, Adamis Labs has now secured distribution contracts and initial stocking orders from the three major wholesalers of prescription drugs in the U.S.

11 Nov 2009

UK research funders announce support for a series of H1N1 2009 research projects

Leading UK research funders today announce -7.5 million of funding for a series of projects aimed at understanding the development and spread of pandemic influenza H1N1 2009 - or 'swine flu'. The research will look at every aspect of the virus, on pig farms, in pig and human populations, and in hospital intensive care units.

11 Nov 2009

FDA Commissioner thanks America's doctors for their efforts during 2009 H1N1 influenza outbreak

Dr. Margaret Hamburg, Commissioner of Food and Drugs, today sent a letter to America's doctors, thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on the safety of the 2009 H1N1 vaccines.

11 Nov 2009

Lower socioeconomic status linked with inability to fight H1N1

People who did not earn a high school diploma could be more likely to get H1N1 and the vaccine might be less effective in them compared to those who earned a diploma, new research shows.

11 Nov 2009

Emory researchers present public health research findings at American Public Health Association meeting

Emory University Rollins School of Public Health researchers will present Nov. 11 on a range of topics at the American Public Health Association's annual meeting in Philadelphia, including a study that found reduced absenteeism among employees participating in a large-scale worksite wellness program.

11 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Negative and positive emotions have a direct impact on pain, says new study

Getting a flu shot this fall? Canadians scientists have found that focusing on a pretty image could alleviate the sting of that vaccine. According to a new Universit- de Montr-al study, published in the latest edition of the Proceedings of the National Academy of Sciences (PNAS), negative and positive emotions have a direct impact on pain.

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.

11 Nov 2009

Also in Global Health: Child sexual abuse in Zimbabwe; dengue outbreak in Cape Verde; program reduces waste in Kenya slums

The Mail & Guardian examines how the "economic collapse" in Zimbabwe has contributed to rising numbers of children falling victims to sexual abuse. "A single clinic in the capital, Harare, says it has treated nearly 30,000 girls and boys who were abused in the past four years - an average of 20 per day." The article examines other contributing factors to the sexual abuse of children in Zimbabwe and a recent program that aims to make schools safe places for Zimbabwe's children (11/10).

11 Nov 2009

GSK to donate 50M H1N1 vaccine doses to WHO in coming months

Drugmaker GlaxoSmithKline announced plans on Tuesday to donate 50 million doses of its H1N1 (swine flu) vaccine to the WHO for use in developing countries within the next few months, Reuters reports. "We expect to start receiving [the first of the H1N1 doses] at the end of the month or early December and that the full 50 million will come by the end of spring," WHO spokesman Gregory Hartl said, adding, "We hope it is the first of many donations."

10 Nov 2009

Aduro BioTech raises funds through its Series A-1 financing

Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.

10 Nov 2009

BioVex completes $70M financing to complete OncoVEX Phase III study

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.

10 Nov 2009

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Kineta, Inc. announced today it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of a larger $13 million award to the University of Washington.

10 Nov 2009

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine.

10 Nov 2009

H1N1 vaccine updates from Pennsylvania Department of Health

The federal Centers for Disease Control and Prevention, or CDC, has allocated a total of 1,351,400 doses of H1N1 vaccine to Pennsylvania to date, the state Department of Health announced today.

10 Nov 2009

Novartis to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical for US$125 million

Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.

10 Nov 2009

Third quarter 2009 financial results announced by Akorn

Akorn, Inc. a specialty pharmaceutical company, today reported financial results for the third quarter ended September 30, 2009.

10 Nov 2009

Vaccine News and Research

Latest Vaccine News and Research

EMS Solutions provides free resources to help companies tackle this year's H1N1 flu pandemic

Drug companies collaborate with nonprofit organizations to fight "neglected" diseases in the developing world

Adamis Labs secures orders from three major wholesale distributers in U.S.

UK research funders announce support for a series of H1N1 2009 research projects

FDA Commissioner thanks America's doctors for their efforts during 2009 H1N1 influenza outbreak

Lower socioeconomic status linked with inability to fight H1N1

Emory researchers present public health research findings at American Public Health Association meeting

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

Negative and positive emotions have a direct impact on pain, says new study

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Also in Global Health: Child sexual abuse in Zimbabwe; dengue outbreak in Cape Verde; program reduces waste in Kenya slums

GSK to donate 50M H1N1 vaccine doses to WHO in coming months

Aduro BioTech raises funds through its Series A-1 financing

BioVex completes $70M financing to complete OncoVEX Phase III study

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

H1N1 vaccine updates from Pennsylvania Department of Health

Novartis to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical for US$125 million

Third quarter 2009 financial results announced by Akorn

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in